Trinity Historical Financial Ratios
| TRIB Stock | USD 1.10 0.02 1.79% |
Trinity Biotech is promptly reporting on over 101 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Average Payables of 3.3 M, Stock Based Compensation To Revenue of 0.0382, Capex To Depreciation of 0.43 or Ev To Sales of 1.34 will help investors to properly organize and evaluate Trinity Biotech plc financial condition quickly.
Trinity |
About Trinity Financial Ratios Analysis
Trinity Biotech plcFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Trinity Biotech investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Trinity financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Trinity Biotech history.
Trinity Biotech Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Trinity Biotech plc stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Trinity Biotech sales, a figure that is much harder to manipulate than other Trinity Biotech plc multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Dividend Yield
Dividend Yield is Trinity Biotech plc dividend as a percentage of Trinity Biotech stock price. Trinity Biotech plc dividend yield is a measure of Trinity Biotech stock productivity, which can be interpreted as interest rate earned on an Trinity Biotech investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.Invested Capital
Invested capital represents the total cash investment that shareholders and debt holders have contributed to Trinity Biotech plc. There are two different methods for calculating Trinity Biotech plc invested capital: operating approach and financing approach. Understanding Trinity Biotech invested capital allows investors to calculate measures of performance such as return on invested capital or return on capital employed.Average Payables
The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.Most ratios from Trinity Biotech's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Trinity Biotech plc current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Trinity Biotech plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. At present, Trinity Biotech's Days Sales Outstanding is projected to slightly grow based on the last few years of reporting. The current year's Stock Based Compensation To Revenue is expected to grow to 0.04, whereas Price To Sales Ratio is forecasted to decline to 0.28.
| 2023 | 2024 (projected) | Dividend Yield | 0.0168 | 0.00952 | Price To Sales Ratio | 0.29 | 0.28 |
Trinity Biotech fundamentals Correlations
Click cells to compare fundamentals
Trinity Biotech Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Trinity Biotech fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Price To Sales Ratio | 0.24 | 0.78 | 0.32 | 0.45 | 0.29 | 0.28 | |
| Ptb Ratio | 4.59 | (35.89) | (93.7) | (15.35) | (0.69) | (0.65) | |
| Days Sales Outstanding | 90.38 | 88.03 | 61.68 | 65.63 | 85.94 | 88.98 | |
| Book Value Per Share | 1.13 | (0.53) | (0.0763) | (0.32) | (3.13) | (2.97) | |
| Free Cash Flow Yield | (0.46) | 0.17 | 0.15 | (0.21) | (0.87) | (0.82) | |
| Operating Cash Flow Per Share | 1.31 | 5.68 | 3.17 | (0.14) | (1.51) | (1.43) | |
| Stock Based Compensation To Revenue | 0.008382 | 0.007766 | 0.0118 | 0.0235 | 0.0364 | 0.0382 | |
| Capex To Depreciation | 3.14 | 3.31 | 3.17 | 2.56 | 0.45 | 0.43 | |
| Pb Ratio | 4.59 | (35.89) | (93.7) | (15.35) | (0.69) | (0.65) | |
| Ev To Sales | 0.96 | 1.54 | 1.11 | 1.14 | 1.41 | 1.34 | |
| Free Cash Flow Per Share | (2.36) | 3.24 | 1.09 | (1.02) | (1.86) | (1.77) | |
| Roic | (0.0498) | 0.21 | 0.2 | (0.19) | (0.87) | (0.83) | |
| Net Income Per Share | (0.97) | (1.44) | 0.21 | (6.08) | (3.14) | (2.98) | |
| Days Of Inventory On Hand | 223.41 | 206.55 | 193.67 | 155.76 | 194.63 | 164.57 | |
| Payables Turnover | 6.68 | 7.52 | 8.12 | 8.5 | 9.62 | 8.36 | |
| Research And Ddevelopement To Revenue | 0.0553 | 0.0589 | 0.0498 | 0.0484 | 0.0771 | 0.071 | |
| Cash Per Share | 4.2 | 6.54 | 6.2 | 0.97 | 0.48 | 0.46 | |
| Pocfratio | 3.95 | 3.35 | 2.26 | (36.26) | (1.42) | (1.35) | |
| Interest Coverage | 0.18 | 3.45 | 2.41 | (0.44) | (2.67) | (2.53) | |
| Capex To Operating Cash Flow | 2.81 | 0.43 | 0.66 | (6.49) | (0.0695) | (0.066) | |
| Pfcf Ratio | (2.19) | 5.87 | 6.57 | (4.84) | (1.15) | (1.21) | |
| Days Payables Outstanding | 54.65 | 48.55 | 44.97 | 42.95 | 37.93 | 66.92 | |
| Income Quality | 0.45 | (3.72) | 15.13 | 0.0225 | 0.48 | 0.82 | |
| Roe | (0.86) | 2.71 | (2.74) | 18.84 | 1.0 | 1.05 | |
| Ev To Operating Cash Flow | 15.94 | 6.59 | 7.79 | (92.37) | (6.94) | (6.59) | |
| Pe Ratio | (5.32) | (13.24) | 34.16 | (0.81) | (0.69) | (0.65) | |
| Return On Tangible Assets | (0.0465) | (0.0623) | 0.0106 | (0.72) | (0.56) | (0.53) | |
| Ev To Free Cash Flow | (8.83) | 11.55 | 22.68 | (12.33) | (5.62) | (5.9) | |
| Earnings Yield | (0.19) | (0.0755) | 0.0293 | (1.23) | (1.46) | (1.39) | |
| Current Ratio | 3.67 | 3.08 | 0.72 | 2.69 | 2.6 | 2.87 | |
| Tangible Book Value Per Share | (9.32) | (8.63) | (8.68) | (5.55) | (5.25) | (4.99) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Trinity Biotech plc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Trinity Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Trinity Biotech Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Trinity Biotech Plc Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Trinity Biotech plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Trinity Biotech. If investors know Trinity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Trinity Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.77) | Earnings Share (2.25) | Revenue Per Share 6.968 | Quarterly Revenue Growth 0.14 | Return On Assets (0.1) |
The market value of Trinity Biotech plc is measured differently than its book value, which is the value of Trinity that is recorded on the company's balance sheet. Investors also form their own opinion of Trinity Biotech's value that differs from its market value or its book value, called intrinsic value, which is Trinity Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Trinity Biotech's market value can be influenced by many factors that don't directly affect Trinity Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Trinity Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Trinity Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Trinity Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.